API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 134 articles Forum Github 13 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NYSE /
  3. NVS.NYSE

Novartis AG ADR (NVS NYSE) stock market data APIs

$117.24 0.59(0.5%) as of September 6, 2024
Price chart is built with Anychart

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG ADR Financial Data Overview

116.65
117.24
-
117.6
116.62
88.7973-120.92
236 543 M
23.8548
2 025 M
48 860 M
1.97
0.0324
0.498
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NVS',
Type: 'Common Stock',
Name: 'Novartis AG ADR',
Exchange: 'NYSE',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000LYF3S8',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '1991-11-18',
InternationalDomestic: 'International/Domestic',
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
HomeCategory: 'ADR',
IsDelisted: false,
}

Novartis AG ADR Fundamental Data is available in our Financial Data APIs

  • Net Revenue 48 860 M
  • EBITDA 19 296 M
  • Earnings Per Share 4.89
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Novartis AG ADR Earnings via APIs

  • Latest Release 2024-07-18
  • EPS/Forecast 1.89

Get Novartis AG ADR End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Novartis AG ADR latest news via APIs

Novartis to License VYGR's Capsid for Gene Therapy in Neurology

Swiss pharma giant Novartis NVS has agreed to license a novel capsid generated from Voyager Therapeutics, Inc’s VYGR capsid platform for use in a gene therapy program. Per Voyager, NVS will use thi...

Jim Cramer Says It Will Take Time For Novartis AG (NVS) To ‘Get The Attention Of Investors’

We recently compiled a list of the Top 10 Stocks on Jim Cramer’s Radar.In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other stocks on Jim Cramer's ra...
Do you have any questions?
support@eodhistoricaldata.com